Ara
Toplam kayıt 1, listelenen: 1-1
Glofitamab in relapsed/refractory diffuse large B cell lymphoma: Real world data
(American Society of Hematology, 2022)
Abstract INTRODUCT ̇ION Glofitamab is a T-cell-engaging bispecific antibody connecting CD20 on B cells and CD3 on T
cells. Although, most of the patients with B-cell non-Hodgkin lymphoma (BNHL) achieve complete response ...